Disease · MONDO_0003145

supratentorial primitive neuroectodermal tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. supratentorial primitive neuroectodermal tumor. Diseases, record MONDO_0003145. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003145

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: supratentorial primitive neuroectodermal tumor; Open Targets
Open Targets ID: MONDO_0003145; Open Targets
Other names: CNS/supratentorial PNET, supratent. primitive neuro. tumor, supratent. primitive neuro. tumour, supratentorial PNET; Open Targets
Disease Ontology: DOID:4791; Disease Ontology
NCI Thesaurus: C6968; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 14 drugs, from ClinicalTrials.gov; Open Targets

Drugs14

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LOMUSTINE	CHEMBL514	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
AMIFOSTINE	CHEMBL1006	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 14

See all 14 drugs

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
DHFR	Dihydrofolate reductase	2	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00085202	Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor	Phase 3	416	2014-02-27	Brain and Central Nervous System Tumors	CISPLATIN, CYCLOPHOSPHAMIDE, FILGRASTIM, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00520936	A Study of Pemetrexed in Children With Recurrent Cancer	Phase 2	72	2011-02-23	Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease), Neuroblastoma (Metaiodobenzylguanidine, Positive Evaluable), Rhabdomyosarcoma, Ependymoma, Non-brainstem High-grade Glioma	PEMETREXED	Open Targets' reading of its record	ClinicalTrials.gov
NCT00303810	Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma	Not applicable	567		Brain and Central Nervous System Tumors	CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, LOMUSTINE, METHOTREXATE, THIOTEPA, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00003211	Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor	Phase 2	94		Brain and Central Nervous System Tumors	AMIFOSTINE, CISPLATIN, CYCLOPHOSPHAMIDE, FILGRASTIM, TOPOTECAN, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00047177	Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor	Phase 2	43		Brain and Central Nervous System Tumors	OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00274911	Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors	Phase 2	30		Brain and Central Nervous System Tumors	CISPLATIN, LOMUSTINE, VINCRISTINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00006258	Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma	Phase 2			Brain and Central Nervous System Tumors	CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, FILGRASTIM, METHOTREXATE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Average-Risk Group vs High-Risk Group: serious adverse events	17 of 269	17 of 144	413	NCT00085202

Source Trial comparisons

Papers from its trials16

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21636711	RESULT	1	PubMed
18309946	RESULT	1	PubMed
17019740	RESULT	1	PubMed
17012043	RESULT	1	PubMed
11835236	RESULT	1	PubMed
39178158	DERIVED	1	PubMed
34714708	DERIVED	1	PubMed
33743477	DERIVED	1	PubMed
33502920	DERIVED	1	PubMed
33405951	DERIVED	1	PubMed

1 to 10 of 16

See all 16 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003145

GET https://conductscience.org/api/diseases/v1/MONDO_0003145/targets?page=2

API reference For AI assistants